High-Grade Glioma – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘High-Grade Glioma – Drugs In Development, 2023’, provides an overview of the High-Grade Glioma pipeline landscape.
The report provides comprehensive information on the therapeutics under development for High-Grade Glioma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for High-Grade Glioma and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of High-Grade Glioma
- The report reviews pipeline therapeutics for High-Grade Glioma by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved High-Grade Glioma therapeutics and enlists all their major and minor projects
- The report assesses High-Grade Glioma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for High-Grade Glioma
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for High-Grade Glioma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding High-Grade Glioma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
9 Meters Biopharma IncAadi Bioscience Inc
Advenchen Laboratories LLC
Aminex Therapeutics Inc
AngioChem Inc
ApolloBio Corp
Aucentra Therapeutics Pty Ltd
Aveta Biomics Inc
Basilea Pharmaceutica Ltd
Bayer AG
BeiGene Ltd
Beijing Pearl Biotechnology LLC
Bellicum Pharmaceuticals Inc
Bexion Pharmaceuticals Inc
Bio-Cancer Treatment International Ltd
Biomimetix JV LLC
Biotech Pharmaceutical Co Ltd
Black Diamond Therapeutics Inc
Blueprint Medicines Corp
BPGbio Inc
Bristol-Myers Squibb Co
Candel Therapeutics Inc
Capital Medical University
Catholic University of Leuven
Cellectar Biosciences Inc
Changzhou Qianhong Bio-Pharma Co Ltd
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Chimerix Inc
CSPC Pharmaceutical Group Ltd
Curtana Pharmaceuticals Inc
Denovo Biopharma LLC
DNAtrix Inc
Duke University
Eisai Co Ltd
Erimos Pharmaceuticals LLC
Everfront Biotech Inc
F. Hoffmann-La Roche Ltd
Fore Biotherapeutics Inc
Gan & Lee Pharmaceuticals Co Ltd
Genexine Inc
Hangzhou NeoVax Biotechnology Co Ltd
Immunomic Therapeutics Inc
Immvira Co Ltd
IN8bio Inc
Ipsen SA
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
Jubilant Therapeutics Inc
Juntendo University Hospital
Karyopharm Therapeutics Inc
Mana Therapeutics Inc
MimiVax LLC
NeoImmuneTech Inc
Northwest Biotherapeutics Inc
Novartis AG
Oblato Inc
Oncotelic Therapeutics Inc
OncoTherapy Science Inc
Patrys Ltd
Pfizer Inc
Plus Therapeutics Inc
Prelude Therapeutics Inc
PTC Therapeutics Inc
Regeneron Pharmaceuticals Inc
Reglagene Holding Inc
Rigel Pharmaceuticals Inc
Royan Institute
Shenzhen Zhenxing Pharmaceutical Technology
Shizuoka Cancer Center
SignPath Pharma Inc
Siren Biotechnology Inc
SK Life Science Inc
SonALASense Inc
SooChow University
Starlight Therapeutics Inc
StemGen SpA
Stemline Therapeutics Inc
StemVax LLC
Sumitomo Pharma Co Ltd
Suzhou Maximum Bio-tech Co Ltd
Systimmune Inc
Targepeutics Inc
TheraBiologics Inc
University Hospital Antwerp
University of Florida
University of Miami
Valerio Therapeutics SA
VCN Biosciences SL
Wayshine Biopharma Inc
WPD Pharmaceuticals Inc
Wurzburg University Hospital
Xynomic Pharmaceuticals Holdings Inc
Yale University
Zhejiang Yangshengtang Biotech Co Ltd